Gilead Sciences Inc: Can GILD Stock Make A Comeback In 2017?

Gilead Stock Is Poised To Rise

Gilead Sciences (NASDAQ:GILD) has underperformed the market with its stock price down almost 25% compared to a 10.33% gain in Nasdaq Composite (INDX:COMPX) and 14.60% gain of Dow Jones Industrial Average (INDX:INDU). Gilead and Amgen (NASDAQ:AMGN) have had a very tough year, so it is interesting to know if now is the time to invest in GILD stock, not from a bottom fishing point of investing, which is often too risky, but on some solid financial and fundamentals arguments.

Strong Fundamentals

The 4-year increase in total revenues, net income and free cash flow, are very positive and bullish for Gilead stock. Gilead's revenues grew by 31.13% in FY 2015, compared to FY 2014 to $32.64B. Net income grew 49.64% to $18.11B. On a quarterly basis, Gilead's revenues fell 3.55% in Sep'16 as compared to Jun'16 to $7.50B. Net income fell 4.78% to $3.33B. Net cash provided by operating activities has risen 58.60% in FY 2015 to $20.329 billion compared to $12.818 billion in the previous year.

Also Read: Is GILD Stock A Good Buy Despite The Recent Slowdown?

Free cash flow has also shown an increase of 59.70% to $19.582 billion in 2015 compared to $12.261 billion in 2014. The EPS has also shown a consistent 5-year growth, diluted EPS in 2015 came in at $11.91 up 62% from $7.35 in the previous year. On a quarterly basis, the diluted earnings per share shows a steady trend ranging from $2.53 in Q1 to $2.49 during Q3.

What about a comparative analysis of the stock to the Biotechnology industry and Healthcare sector?

Financial Ratio Company Industry Sector
P/E Ratio (TTM) 6.94 42.48 30.46
Price to Sales (TTM) 3.12 98.64 7.94
Price to Cash Flow (TTM) 6.08 28.05 23.16
Price to Book (MRQ) 5.87 12.81 5.32
Current Ratio (MRQ) 1.93 6.30 3.33
Total Debt to Equity (MRQ) 160.49 41.01 30.47
Operating Margin (TTM) 60.83 -604.80 7.87
Net Profit Margin (TTM) 47.74 -619.86 4.26
Return on Equity (TTM) 87.95 -3.90 16.35
Sales - 5 Yr. Growth Rate 32.64 22.27 10.81
EPS - 5 Yr. Growth Rate 48.28 17.25 9.38

Sources: Money MSN,

We can clearly see that Gilead stock is not expensive, on the contrary, it seems to be undervalued compared to the Biotechnology industry and the Healthcare sector. It has much better profit margins and is financially strong, although high debt to equity ratio is of major concern. And I like the consistent growth in sales and earnings per share as key drivers of profitability and higher stock price.

Will The US Government Act On Drug Pricing

A very alarming factor to consider is the possibility of the new US government bringing down drugs prices and medicines, as this will be a major challenge to profitability. In a recent tweet, President-elect Mr. Trump mentioned that his intentions are to lower the drugs prices.  The pharmaceutical stocks like Pfizer (NYSE:PFE) took a dive after that tweet. It is important to clarify that as of now it is not a fact but a mere intention. It could well remain an intention. In case there is an action about lowering drugs and medicine prices, then this clearly is not a good thing for Gilead shareholders. There is also a major discussion on the reform of healthcare sector, but still, we will have to wait and see if plans will become actions.

Also Read: New Revolutionary Drugs To Drive Gilead Sciences, Inc

Technical Analysis Seems Bullish

There has been a strong base support level around $70 per share, plus the stock price has closed above daily 50 moving average currently at 73.91. MACD is bullish, and ADX indicator shows that +DI has crossed above –DI, which is also very bullish. The accumulation/distribution line shows a rising trend and this is required for an up move. Money Flow Index is also rising showing increasing buying pressure from current levels. And the stock has formed a triple bottom at the region $70-$72.


Gilead stock seems well poised for an up move from current levels of about $75.5 per share. It is a very profitable company with an improved technical analysis picture and seems undervalued relatively compared to its industry and sector. It has a current beta of 1.20 which means it is more volatile stock than the general stock market, but could well provide a good risk-adjusted return in 2017.

Stavros Georgiadis Stavros Georgiadis   on Amigobulls :
Author's Disclosures & Disclaimers:
  • I do not hold any positions in the stocks mentioned in this post and don't intend to initiate a position in the next 72 hours
  • I am not being compensated for this post (except possibly by Amigobulls).
  • I do not have any business relationship with the companies mentioned in this post.
  • See Amigobulls' policy on anonymous authors who use a pseudonym
Amigobulls Disclosures & Disclaimers:

This post has been submitted by an independent external contributor. This author may or may not hold any positions in the stocks discussed. Neither Amigobulls, nor any members of its staff hold positions in any of the stocks discussed in this post. Amigobulls has not verified the author’s positions in the stocks discussed, and does not provide any guarantees in this regard. The author may be paid by Amigobulls for this contribution, under the paid contributors program. However, Amigobulls does not guarantee the authenticity or accuracy of the information provided by the author in this post.

The author may not be a qualified investment advisor. The opinions stated in the post should not be treated as investment advice. Buying and selling of securities carries the risk of monetary losses. Readers/Viewers are advised to carry out their own due diligence and consult their investment advisors before making any investment decisions.

Amigobulls does not have any business relationship with any of the companies covered in this post. This post represents the views of the author/contributor and may not reflect the views of Amigobulls.

At Amigobulls, we prefer that our authors disclose their real names. However, due to a variety of reasons, author's may prefer otherwise. Recognizing the fact that the ideas conveyed carry greater significance, and to facilitate the dissemination of these ideas, we allow authors to use a pseudonym. However, we do collect the same of details from anonymous authors, as we do from others, like the author's real name and contact information. Of course, this information remains confidential with us, and is not displayed on the site.
Further, to protect the interests of our readers/viewers, anonymous authors are required to make the same set of disclosures as other authors. For more details, you can write to any of our in-house editors at

show more

Comments on this article and GILD stock

Do share this awesome post